3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Fluorouracil
255
Leucovorin
224
Oxaliplatin
218
Irinotecan
206
Bevacizumab
200
Capecitabine
144
Cetuximab
136
Panitumumab
68
Folfox protocol
63
regorafenib
50
Colonoscopy
44
pembrolizumab
42
IFL protocol
39
Radiotherapy
32
Nivolumab
31
Drug Therapy
27
trifluridine tipiracil drug combination
26
Gemcitabine
24
Blood Specimen Collection
23
Chemotherapy, Adjuvant
20
Surveys and Questionnaires
19
Celecoxib
19
Surgical Procedures, Operative
16
durvalumab
15
Neoadjuvant Therapy
15
Cyclophosphamide
14
Cisplatin
14
aflibercept
13
Standard of Care
13
Pemetrexed
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colorectal Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled